NCT05786521

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 65 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Conditions

• Aging
• Diabetes Mellitus, Type 2
• PreDiabetes
• Overweight and Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide Injectable Product	Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
BEHAVIORAL	Lifestyle Counseling	Lifestyle Counseling will be provided throughout study intervention

Timeline

• Start date: 2023-04-01
• Primary completion: 2024-05-20
• Completion: 2024-05-20
• First posted: 2023-03-27
• Last updated: 2025-05-04
• Results posted: 2025-05-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study